Cellectis S.A. (NASDAQ:CLLS) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET

Company Participants

Arthur Stril - Chief Business Officer

Andre Choulika - Chief Executive Officer

Bing Wang - Chief Financial Officer

Conference Call Participants

Gena Wang - Barclays

Ashiq Mubarack - Citi

Hartaj Singh - Oppenheimer

Jack Allen - Baird

David Dai - SMBC

Silvan Tuerkcan - JMP Securities

Nicolas Abbott - Wells Fargo

Operator

Good morning, everyone, and welcome to the Cellectis Second Quarter 2020 Earnings Call. At this time, all participants are in listen-only-mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. Please be aware that today's conference call is being recorded.

I'd now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin.

Arthur Stril

Good morning, and welcome, everyone to Cellectis second quarter 2022 corporate update and financial results conference call. Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; and Dr. Bing Wang, our Chief Financial Officer. Dr. Brownstein is absent on today's call, so I will be speaking about our CAR-T program update.

Yesterday evening, Cellectis filed its interim report and issued a press release reporting its financial results for the second quarter and six months period ended June 30, 2022. The report and press release are available on our website at cellectis.com. As a reminder, we will make statements regarding selective financial outlook in addition to its manufacturing, regulatory and product development plans. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the SEC and the financial report, including the management report for the year ending on December 31, 2021, and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time.

I would now like to turn the call over to Andre.

Andre Choulika

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Like Cellectis to make progress enrolling patients in our three sponsored Phase I dose escalation trials and take notable steps forward with our preclinical data and programs.